Vaxcyte, Inc. (PCVX) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है San Carlos, CA, United States. वर्तमान CEO हैं Grant E. Pickering.
PCVX के पास है IPO तिथि 2020-06-12, 414 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $8.7B.
Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel protein vaccines to prevent and treat bacterial infectious diseases. The company's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials for invasive pneumococcal disease and pneumonia. Vaxcyte's pipeline also includes VAX-XP to address emerging strains and antibiotic resistance, VAX-A1 targeting Group A Strep, and VAX-PG designed to treat periodontitis. Founded in 2013 and headquartered in San Carlos, California, the company was formerly known as SutroVax, Inc. before rebranding in May 2020.
